 |
|  |
Oct-04-18 | Reiterated |
Needham |
Buy |
$36 → $39 |
|
Aug-02-18 | Reiterated |
Stifel |
Buy |
$32 → $34 |
|
Aug-02-18 | Reiterated |
Needham |
Buy |
$32 → $36 |
|
Jun-18-18 | Reiterated |
Needham |
Buy |
$26 → $32 |
|
Apr-27-18 | Reiterated |
Needham |
Buy |
$23 → $26 |
|
Jan-16-18 | Reiterated |
Needham |
Buy |
$25 → $23 |
|
Nov-02-17 | Reiterated |
Needham |
Buy |
$26 → $25 |
|
Jul-28-17 | Reiterated |
Needham |
Buy |
$25 → $26 |
|
May-30-17 | Resumed |
Piper Jaffray |
Overweight |
|
|
Jun-30-16 | Resumed |
JMP Securities |
Mkt Outperform |
|
|
Oct-28-15 | Reiterated |
Needham |
Buy |
$30 → $23 |
|
Oct-06-15 | Reiterated |
Needham |
Buy |
$32 → $30 |
|
Oct-06-15 | Reiterated |
Canaccord Genuity |
Buy |
$31 → $28 |
|
Aug-04-15 | Reiterated |
Needham |
Buy |
$29 → $32 |
|
Jul-29-15 | Reiterated |
Needham |
Buy |
$26 → $29 |
|
Jul-28-15 | Reiterated |
Dougherty & Company |
Buy |
$25 → $30 |
|
Mar-25-15 | Reiterated |
Stifel |
Buy |
$22 → $25 |
|
Mar-25-15 | Reiterated |
Canaccord Genuity |
Buy |
$26 → $28 |
|
Mar-23-15 | Reiterated |
Needham |
Buy |
$21 → $26 |
|
Mar-09-15 | Initiated |
Needham |
Buy |
$21 |
|
|
 |
Feb-12-19 08:00AM | AtriCure Announces Launch of the cryoICE® cryoSPHERE Probe Business Wire |
Feb-05-19 08:00AM | AtriCure Announces the First Patient Enrolled in the ICE-AFIB Clinical Trial Business Wire |
Feb-04-19 08:30AM | AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results Business Wire |
Jan-31-19 09:19AM | AtriCure (ATRC) Upgraded to Strong Buy: Here's What You Should Know Zacks |
Jan-28-19 07:25AM | Recent Analysis Shows Textron, Occidental Petroleum, AtriCure, Chegg, KBR, and V.F. Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
Jan-08-19 02:36PM | Who Has Been Buying AtriCure, Inc. (NASDAQ:ATRC) Shares? Simply Wall St. |
09:56AM | Here's how Dayton-area stocks performed in 2018 American City Business Journals |
Jan-07-19 08:30AM | AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018 Business Wire |
Jan-02-19 02:03PM | These were the best Cincinnati stocks in 2018 American City Business Journals |
Dec-27-18 08:47AM | Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears Zacks |
Dec-24-18 10:04AM | Perrigo Plunges on $1.9B Tax Bill From Irish Government Zacks |
Dec-13-18 08:00AM | AtriCure to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire |
05:02AM | Hedge Funds Are Crazy About AtriCure Inc. (ATRC) Insider Monkey |
Nov-30-18 01:47PM | What Kind Of Shareholders Own AtriCure Inc (NASDAQ:ATRC)? Simply Wall St. |
Nov-12-18 08:40AM | Detailed Research: Economic Perspectives on Roku, Exelixis, Scientific Games, Boot Barn, Astronics, and AtriCure What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.56% |
Nov-08-18 09:30AM | AtriCure to Present at the Piper Jaffray 30th Annual Healthcare Conference Business Wire |
05:20AM | Edited Transcript of ATRC earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents |
Nov-01-18 06:35PM | AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates Zacks |
05:30PM | AtriCure: 3Q Earnings Snapshot Associated Press |
04:01PM | AtriCure Reports Third Quarter 2018 Financial Results Business Wire |
Oct-22-18 04:01PM | AtriCure to Participate in Upcoming Investor Conferences Business Wire |
Oct-16-18 02:12PM | Is AtriCure Inc (NASDAQ:ATRC) A Financially Sound Company? Simply Wall St. |
Oct-12-18 09:10AM | Report: Developing Opportunities within Agree Realty, Lattice Semiconductor, American Outdoor Brands, Schneider National, AtriCure, and Universal Display Future Expectations, Projections Moving into 2018 GlobeNewswire |
Oct-11-18 08:00AM | AtriCure to Announce Third Quarter 2018 Financial Results Business Wire |
Oct-10-18 05:20PM | These Cincinnati stocks took the biggest hit amid Dows worst loss since February American City Business Journals -6.15% |
Oct-08-18 10:04AM | AtriCure (ATRC) Looks Good: Stock Adds 6.8% in Session Zacks |
Oct-05-18 04:29PM | Why Chefs' Warehouse, SMART Global Holdings, and AtriCure Jumped Today Motley Fool +6.76% |
08:35AM | The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker Benzinga |
Oct-04-18 06:09PM | AtriCure Announces Pricing of Public Offering of Common Stock Business Wire -8.19% |
07:59AM | The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut Benzinga |
Oct-03-18 04:01PM | AtriCure Reports Preliminary Financial Results for Third Quarter 2018 Business Wire |
04:01PM | AtriCure Announces Proposed Public Offering of Common Stock Business Wire |
Aug-28-18 08:00AM | AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial Business Wire |
Aug-21-18 08:00AM | AtriCure to Present at the Morgan Stanley Global Healthcare Conference Business Wire |
Aug-13-18 03:29AM | Edited Transcript of ATRC earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents |
Aug-08-18 08:25AM | Report: Exploring Fundamental Drivers Behind BancFirst, Materion, Acuity Brands, USA Truck, Marriott International, and AtriCure New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
Aug-01-18 06:45PM | AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates Zacks |
05:38PM | AtriCure: 2Q Earnings Snapshot Associated Press |
04:01PM | AtriCure Reports Second Quarter 2018 Financial Results Business Wire |
Jul-24-18 04:30PM | ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Directors PR Newswire |
Jul-20-18 12:50PM | AtriCure Made an Important Upside Breakout TheStreet.com |
Jul-16-18 08:00AM | AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference Business Wire |
Jul-11-18 08:00AM | AtriCure to Announce Second Quarter 2018 Financial Results Business Wire |
Jul-02-18 05:16AM | The List: Dayton-Area Public Company Executive Compensation American City Business Journals |
Jun-15-18 02:44PM | AtriCure stock hits 52-week high American City Business Journals +7.74% |
Jun-12-18 08:00AM | AtriCure Announces 2018 Analyst and Investor Meeting Business Wire |
Jun-05-18 06:00AM | AtriCure and Baheal Group Establish Partnership and China Distribution Agreement Business Wire |
Jun-01-18 08:15AM | The List: Dayton-Area Top 100 Companies American City Business Journals |
May-31-18 01:19PM | 7 Greater Cincinnati firms among Ohio's 30 top-paying companies: SLIDESHOW American City Business Journals |
May-30-18 04:21PM | These are Ohio's 30 top paying companies (Countdown) American City Business Journals |
May-08-18 02:40PM | These Cincinnati public companies pay their employees the most: SLIDESHOW American City Business Journals |
Apr-27-18 06:03PM | Edited Transcript of ATRC earnings conference call or presentation 26-Apr-18 8:30pm GMT Thomson Reuters StreetEvents +8.54% |
12:26PM | Here's why AtriCure stock is surging American City Business Journals |
Apr-26-18 06:11PM | AtriCure: 1Q Earnings Snapshot Associated Press |
04:05PM | AtriCure Reports First Quarter 2018 Financial Results Business Wire |
Apr-10-18 03:19PM | Is There Now An Opportunity In AtriCure Inc (NASDAQ:ATRC)? Simply Wall St. |
Apr-09-18 07:30AM | Free Post Earnings Research Report: AtriCures Quarterly Revenues Jumped 11.9%; Net Loss Narrowed ACCESSWIRE |
Apr-05-18 08:00AM | AtriCure to Announce First Quarter 2018 Financial Results Business Wire |
Mar-15-18 08:00AM | AtriCure to Present at the Needham & Companys 17th Annual Healthcare Conference Business Wire |
Mar-09-18 07:40AM | Free Research Report as ConforMIS Reported Better Than Expected Results ACCESSWIRE |
Mar-02-18 07:40AM | Report: Developing Opportunities within LCI Industries, Biglari, Graco, Federal Signal, AtriCure, and Perry Ellis International Future Expectations, Projections Moving into 2018 GlobeNewswire |
Feb-28-18 09:48PM | AtriCure Inc (ATRC) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com -6.95% |
10:11AM | Edited Transcript of ATRC earnings conference call or presentation 26-Feb-18 9:30pm GMT Thomson Reuters StreetEvents |
Feb-26-18 05:36PM | AtriCure reports 4Q loss Associated Press |
04:05PM | AtriCure Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire |
12:00PM | AtriCure, Inc. to Host Earnings Call ACCESSWIRE |
11:27AM | AtriCure Q4 Earnings Outlook Benzinga |
Feb-22-18 08:00AM | AtriCure Launches the AtriClip® FLEXV Device in the United States Business Wire +5.57% |
Feb-20-18 05:01PM | Cincinnati medical device maker gets board refresh American City Business Journals |
08:00AM | AtriCure Names Scott Drake Board Chairman Business Wire |
Feb-07-18 08:00AM | AtriCure to Announce Fourth Quarter and Full Year 2017 Financial Results Business Wire |
Jan-08-18 08:00AM | AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017 Business Wire |
07:35AM | Factors of Influence in 2018, Key Indicators and Opportunity within Insys Therapeutics, LGI Homes, Steelcase, AtriCure, Alliance Holdings GP, and Digital Turbine New Research Emphasizes Economic Growth GlobeNewswire |
Dec-14-17 04:05PM | AtriCure to Present at the 36th Annual JP Morgan Healthcare Conference Business Wire |
Dec-11-17 01:31PM | ETFs with exposure to AtriCure, Inc. : December 11, 2017 Capital Cube |
Dec-01-17 10:26AM | ETFs with exposure to AtriCure, Inc. : December 1, 2017 Capital Cube |
Nov-20-17 11:41AM | ETFs with exposure to AtriCure, Inc. : November 20, 2017 Capital Cube |
Nov-09-17 04:05PM | AtriCure to Present at the Piper Jaffray 29th Annual Healthcare Conference Business Wire |
Nov-08-17 05:37PM | ETFs with exposure to AtriCure, Inc. : November 8, 2017 Capital Cube |
Nov-07-17 08:10AM | AtriCure, Inc. :ATRC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube |
Nov-02-17 09:05PM | Edited Transcript of ATRC earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents -7.77% |
Nov-01-17 05:33PM | AtriCure reports 3Q loss Associated Press |
04:05PM | AtriCure Reports Third Quarter 2017 Financial Results Business Wire |
Oct-26-17 11:01AM | AtriCure, Inc. Value Analysis (NASDAQ:ATRC) : October 26, 2017 Capital Cube |
Oct-25-17 08:15AM | AtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : October 25, 2017 Capital Cube |
Oct-20-17 08:00AM | AtriCure to Present at the Stifel Healthcare Conference Business Wire |
Oct-11-17 11:11AM | Mike Hooven, Founder of AtriCure (NASDAQ: ATRC) and Enable Injections, Joins Genetesis Board of Directors Business Wire |
Oct-10-17 08:00AM | AtriCure to Announce Third Quarter 2017 Financial Results Business Wire |
Sep-28-17 08:17AM | AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : September 28, 2017 Capital Cube |
Sep-12-17 08:00AM | AtriCure Announces U.S. Launch of the AtriClip® PROV Device Business Wire |
Sep-03-17 11:50PM | Edited Transcript of ATRC earnings conference call or presentation 27-Jul-17 8:30pm GMT Thomson Reuters StreetEvents |
Aug-18-17 05:00PM | AtriCure to Present at the Morgan Stanley Global Healthcare Conference Business Wire |
Aug-15-17 03:22PM | ETFs with exposure to AtriCure, Inc. : August 15, 2017 Capital Cube |
09:08AM | AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : August 15, 2017 Capital Cube |
Aug-04-17 07:47AM | Stock surge on Wall Street pushes these 25 S&P 500 stocks to record highs American City Business Journals |
Aug-01-17 11:10AM | AtriCure, Inc. :ATRC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Capital Cube |
Jul-28-17 09:34AM | AtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : July 28, 2017 Capital Cube +5.07% |
Jul-27-17 11:57PM | AtriCure reports 2Q loss Associated Press |
04:05PM | AtriCure Reports Second Quarter 2017 Financial Results Business Wire |
11:30AM | Investor Network: AtriCure, Inc. to Host Earnings Call ACCESSWIRE |
|
|
|
 |
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Wade M. Andrew | SVP and CFO | Jan 28 | Option Exercise | 1.50 | 1,000 | 1,500 | 181,787 | Jan 28 04:07 PM | Noznesky Justin J | SVP, Mktg & Business Develop | Aug 15 | Sale | 30.32 | 4,000 | 121,280 | 124,920 | Aug 17 07:54 AM | Collar Mark A | Director | Jun 14 | Sale | 25.00 | 2,090 | 52,250 | 66,898 | Jun 18 06:28 AM | Noznesky Justin J | SVP, Mktg & Business Develop | May 15 | Sale | 23.05 | 4,000 | 92,200 | 131,920 | May 17 04:28 PM | Krell Elizabeth D | Director | May 08 | Sale | 22.82 | 10,000 | 228,200 | 19,967 | May 09 09:00 AM | Krell Elizabeth D | Director | May 07 | Option Exercise | 9.30 | 10,000 | 93,000 | 29,967 | May 09 09:00 AM | Krell Elizabeth D | Director | Mar 13 | Sale | 20.00 | 10,000 | 200,000 | 19,967 | Mar 14 04:34 PM | Krell Elizabeth D | Director | Mar 12 | Option Exercise | 14.17 | 10,000 | 141,700 | 29,967 | Mar 14 04:34 PM | Lanning Mark R | Director | Mar 02 | Option Exercise | 10.10 | 10,000 | 101,000 | 99,005 | Mar 02 04:49 PM | GROVES REGINA E | Director | Mar 01 | Buy | 17.43 | 1,000 | 17,430 | 10,469 | Mar 01 04:03 PM | Drake Scott William | Director | Mar 01 | Buy | 17.64 | 11,000 | 194,040 | 16,805 | Mar 02 04:38 PM |
|
 |
|
 |
|
 |
|
Index | - |
P/E | - |
EPS (ttm) | -0.89 |
Insider Own | 3.50% |
Shs Outstand | 54.07M |
Perf Week | 1.86% |
Market Cap | 1.19B |
Forward P/E | - |
EPS next Y | -0.14 |
Insider Trans | -29.25% |
Shs Float | 51.64M |
Perf Month | 33.66% |
Income | -43.50M |
PEG | - |
EPS next Q | -0.03 |
Inst Own | 83.90% |
Short Float | 6.63% |
Perf Quarter | 42.25% |
Sales | 66.20M |
P/S | 17.90 |
EPS this Y | -486.40% |
Inst Trans | 3.00% |
Short Ratio | 7.29 |
Perf Half Y | 51.70% |
Book/sh | 1.02 |
P/B | 21.49 |
EPS next Y | 39.10% |
ROA | -15.00% |
Target Price | 20.08 |
Perf Year | 153.41% |
Cash/sh | 1.00 |
P/C | 21.87 |
EPS next 5Y | 15.00% |
ROE | -25.70% |
52W Range | 8.60 - 23.05 |
Perf YTD | 31.26% |
Dividend | - |
P/FCF | - |
EPS past 5Y | -8.00% |
ROI | -230.40% |
52W High | -4.90% |
Beta | -0.36 |
Dividend % | - |
Quick Ratio | 3.80 |
Sales past 5Y | -10.70% |
Gross Margin | 79.20% |
52W Low | 154.88% |
ATR | 0.82 |
Employees | 116 |
Current Ratio | 3.90 |
Sales Q/Q | 69.00% |
Oper. Margin | -15.00% |
RSI (14) | 70.21 |
Volatility | 3.31% 4.36% |
Optionable | Yes |
Debt/Eq | 0.00 |
EPS Q/Q | 82.50% |
Profit Margin | -14.30% |
Rel Volume | 1.00 |
Prev Close | 21.79 |
Shortable | Yes |
LT Debt/Eq | 0.00 |
Earnings | Mar 07 AMC |
Payout | - |
Avg Volume | 469.57K |
Price | 21.92 |
Recom | 1.70 |
SMA20 | 14.32% |
SMA50 | 18.85% |
SMA200 | 34.17% |
Volume | 469,497 |
Change | 0.60% |
|
|
 |
|  |
Jan-17-19 | Upgrade |
First Analysis Sec |
Neutral → Outperform |
$12 → $19 |
|
May-16-18 | Initiated |
Stephens |
Overweight |
$16 |
|
Oct-13-17 | Reiterated |
H.C. Wainwright |
Buy |
$8 → $8.50 |
|
May-31-17 | Initiated |
Jefferies |
Buy |
$8 |
|
Jan-26-17 | Downgrade |
First Analysis Sec |
Overweight → Equal-Weight |
$5.50 |
|
Jan-04-17 | Upgrade |
Ladenburg Thalmann |
Neutral → Buy |
|
|
Jan-06-16 | Initiated |
H.C. Wainwright |
Buy |
$6 |
|
|
 |
Feb-14-19 07:00AM | Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria GlobeNewswire |
Feb-06-19 07:00AM | Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan GlobeNewswire |
Feb-05-19 04:36PM | A Pact With Merck Sent This Biotech Stock Zooming Near A Breakout Investor's Business Daily +6.09% |
03:44PM | Here's Why Codexis Gained as Much as 9.8% Today Motley Fool |
07:47AM | The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results Benzinga |
Feb-04-19 04:05PM | Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck GlobeNewswire |
Jan-30-19 06:00PM | 3 Top Stocks Under $20 Motley Fool |
Jan-14-19 05:04PM | 2 Top Small-Cap Stocks to Buy in January Motley Fool |
Jan-02-19 10:55AM | Do Institutions Own Codexis, Inc. (NASDAQ:CDXS) Shares? Simply Wall St. |
Dec-05-18 06:18PM | Edited Transcript of CDXS earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents |
Nov-28-18 08:45AM | Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. Future Expectations, Projections Moving into 2018 GlobeNewswire +7.18% |
Nov-14-18 02:39PM | This Small-Cap Biotech is Quietly Setting the Stage For a Big 2019 Motley Fool |
Nov-13-18 12:11PM | Should You Worry About Codexis Incs (NASDAQ:CDXS) CEO Pay? Simply Wall St. |
Nov-08-18 07:20PM | Codexis (CDXS) Reports Break-Even Earnings for Q3 Zacks |
06:16PM | Codexis: 3Q Earnings Snapshot Associated Press |
04:05PM | Codexis Reports Third Quarter 2018 Financial Results GlobeNewswire |
07:00AM | Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114 GlobeNewswire |
Nov-07-18 04:05PM | Codexis to Present at Two Investment Conferences in November GlobeNewswire +6.34% |
Nov-01-18 11:28AM | Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know Zacks |
07:00AM | Codexis to Hold Third Quarter 2018 Conference Call on November 8 GlobeNewswire |
Oct-17-18 07:20AM | Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire |
Oct-06-18 08:35AM | Better Synthetic Biology Stock: Amyris vs. Codexis Motley Fool |
Oct-01-18 07:00AM | Codexis Appoints Claus Ladefoged to Global Enzyme Business Development Role GlobeNewswire |
Sep-12-18 04:27PM | Edited Transcript of CDXS earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents |
Sep-11-18 07:11AM | The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor Zacks |
Sep-10-18 09:23AM | 5 Top-Ranked Nasdaq Stocks Defying the Worst September Start Zacks |
Sep-05-18 02:33PM | Codexis Inc (NASDAQ:CDXS): Did It Outperform The Industry? Simply Wall St. |
Sep-04-18 03:31PM | Here's Why Codexis Gained 19.4% in August Motley Fool |
Aug-29-18 07:00AM | Codexis to Present at Three Investment Conferences in September GlobeNewswire |
Aug-20-18 08:10AM | Report: Exploring Fundamental Drivers Behind Codexis, Kornit Digital, NewLink Genetics, NCS Multistage, Mountain Province Diamonds, and CSS Industries New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
Aug-17-18 12:50PM | 4 Under-the-Radar Small Cap Stars Investopedia |
Aug-15-18 09:58AM | E-commerce, Favorable Markets Drive Growth at Grainger (GWW) Zacks |
Aug-08-18 08:55PM | Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates Zacks |
07:48PM | Codexis: 2Q Earnings Snapshot Associated Press |
04:05PM | Codexis Reports Second Quarter 2018 Financial Results GlobeNewswire |
02:30PM | Codexis, Inc. to Host Earnings Call ACCESSWIRE |
Aug-01-18 07:00AM | Codexis to Hold Second Quarter 2018 Conference Call on August 8 GlobeNewswire |
Jul-11-18 07:00AM | Codexis Appoints Dr. Hicham Alaoui, Veteran Drug Discoverer, as Vice President, Biotherapeutics Research & Development GlobeNewswire |
Jul-09-18 08:00AM | Codexis Doses First Subjects in Phase 1a Trial of CDX-6114 GlobeNewswire |
Jul-06-18 07:20AM | Free Technical Research on Clovis Oncology and Three More Biotech Equities ACCESSWIRE |
Jun-21-18 08:19AM | 3 Growth Stocks I'd Buy Right Now Motley Fool |
Jun-16-18 08:46AM | 3 Stocks That Could Put Tesla's Returns to Shame Motley Fool |
Jun-01-18 08:00AM | New Research Coverage Highlights WPP, Codexis, Natural Resource Partners LP, Mercer International, Booking, and SINOPEC Shangai Petrochemical Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
May-29-18 07:00AM | Codexis to Present at Three Upcoming Investment Conferences GlobeNewswire |
May-18-18 04:12AM | Edited Transcript of CDXS earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents |
May-11-18 08:11PM | 3 High-Growth Stocks That Are Just Getting Started Motley Fool +8.58% |
May-10-18 06:40PM | Codexis: 1Q Earnings Snapshot Associated Press |
04:05PM | Codexis Reports First Quarter 2018 Financial Results GlobeNewswire |
May-03-18 07:00AM | Codexis to Hold First Quarter 2018 Conference Call on May 10 GlobeNewswire |
Apr-25-18 07:40AM | Blog Exposure - Codexis Entered into Strategic Collaboration with Porton Pharma Solutions ACCESSWIRE |
Apr-23-18 06:00AM | Porton Pharma Solutions and Codexis Launch Global Partnership Business Wire |
Apr-09-18 08:10AM | New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
Apr-06-18 11:08AM | Why Codexis, Inc. Stock Is Tumbling Today Motley Fool |
Apr-05-18 09:15PM | Codexis Announces Pricing of Public Offering of Common Stock GlobeNewswire |
04:02PM | Codexis Announces Proposed Public Offering of Common Stock GlobeNewswire |
07:00AM | Codexis to Present at H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco GlobeNewswire |
Mar-30-18 03:26PM | Edited Transcript of CDXS earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents |
Mar-25-18 06:35AM | 3 Stocks That Feel Like Microsoft in 1986 Motley Fool |
Mar-13-18 08:10AM | Detailed Research: Economic Perspectives on GRIDSUM HOLDING, Booking, POSCO, Codexis, Third Point Reinsurance, and Arch Capital Group What Drives Growth in Today's Competitive Landscape GlobeNewswire |
Mar-09-18 03:16PM | Here's Why Codexis Dropped as Much as 14.6% Today Motley Fool |
Mar-08-18 06:07PM | Codexis misses Street 4Q forecasts Associated Press |
04:05PM | Codexis Reports 2017 Fourth Quarter and Full Year Financial Results GlobeNewswire |
12:45PM | Codexis, Inc. to Host Earnings Call ACCESSWIRE |
09:32AM | Codexis Q4 Earnings Preview Benzinga |
09:23AM | Codexis Inc (NASDAQ:CDXS): Is Breakeven Near? Simply Wall St. |
Mar-01-18 07:00AM | Codexis to Hold 2017 Fourth Quarter and Full Year Conference Call on March 8 GlobeNewswire |
Feb-23-18 07:56AM | 3 Top Small-Cap Stocks to Buy in February Motley Fool |
Feb-15-18 07:00AM | Codexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes Commercialization GlobeNewswire |
Feb-12-18 07:00AM | Codexis to Present at the 25th International Molecular Medicine Tri-Conference GlobeNewswire |
Jan-22-18 04:08PM | 3 Stocks Wall Street Hasn't Heard of Yet Motley Fool |
Dec-29-17 11:42AM | ETFs with exposure to Codexis, Inc. : December 29, 2017 Capital Cube |
Dec-28-17 08:44AM | Codexis, Inc. :CDXS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017 Capital Cube |
Dec-24-17 08:37AM | 3 Stocks You Can Buy and Hold for the Next Decade Motley Fool |
Dec-16-17 08:36AM | 3 Top Small-Cap Stocks to Buy in December Motley Fool |
Dec-12-17 02:56PM | Codexis, Inc. Value Analysis (NASDAQ:CDXS) : December 12, 2017 Capital Cube +6.94% |
Dec-08-17 07:19AM | Codexis, Inc. breached its 50 day moving average in a Bullish Manner : CDXS-US : December 8, 2017 Capital Cube |
Dec-01-17 11:48AM | Edited Transcript of CDXS earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents |
Nov-29-17 09:16AM | 3 Bioeconomy Stocks That Have a Killer Advantage Motley Fool |
Nov-28-17 12:00PM | ETFs with exposure to Codexis, Inc. : November 28, 2017 Capital Cube |
Nov-26-17 09:03AM | 3 Stocks That Could Put Amazon's Returns to Shame Motley Fool |
Nov-13-17 10:45PM | Edited Transcript of CDXS earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents |
Nov-09-17 06:29PM | Codexis reports 3Q loss Associated Press |
04:05PM | Codexis Reports Financial Results for the Third Quarter of 2017 GlobeNewswire |
12:05PM | Codexis, Inc. to Host Earnings Call ACCESSWIRE |
07:00AM | Codexis to Present at Two Investment Conferences in November GlobeNewswire |
Nov-06-17 07:21AM | Codexis, Inc. breached its 50 day moving average in a Bullish Manner : CDXS-US : November 6, 2017 Capital Cube |
Nov-02-17 11:59AM | ETFs with exposure to Codexis, Inc. : November 2, 2017 Capital Cube |
07:00AM | Codexis to Hold 2017 Third Quarter Conference Call on November 9 GlobeNewswire |
Oct-25-17 07:48AM | 1 Small-Cap Biotech Stock to Buy Right Now Motley Fool |
Oct-23-17 10:27AM | ETFs with exposure to Codexis, Inc. : October 23, 2017 Capital Cube |
Oct-12-17 10:21AM | ETFs with exposure to Codexis, Inc. : October 12, 2017 Capital Cube +17.16% |
08:00AM | Codexis and Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership GlobeNewswire |
Oct-11-17 09:31AM | Codexis, Inc. :CDXS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 11, 2017 Capital Cube |
Oct-09-17 12:32PM | 3 Hot Stocks Under $10 Investopedia |
Oct-04-17 07:45AM | 3 Top Small-Cap Stocks to Buy in October Motley Fool |
Aug-31-17 07:00AM | Codexis to Present at Four Investment Conferences in September GlobeNewswire |
Aug-24-17 02:05PM | Edited Transcript of CDXS earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents |
Aug-16-17 02:07PM | 3 Stocks Set to Pop Motley Fool |
Aug-09-17 10:14PM | Codexis reports 2Q loss Associated Press |
04:05PM | Codexis Reports Financial Results for the Second Quarter of 2017 GlobeNewswire |
|
|
|
 |
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
SANGSTER GORDON | SVP & Chief Financial Officer | Jan 25 | Option Exercise | 3.39 | 40,000 | 135,600 | 174,453 | Jan 28 06:00 PM | SANGSTER GORDON | SVP & Chief Financial Officer | Jan 25 | Sale | 17.11 | 40,000 | 684,236 | 134,453 | Jan 28 06:00 PM | SANGSTER GORDON | SVP & Chief Financial Officer | Jan 24 | Option Exercise | 3.39 | 35,000 | 118,650 | 169,453 | Jan 28 06:00 PM | SANGSTER GORDON | SVP & Chief Financial Officer | Jan 24 | Sale | 16.74 | 35,000 | 585,942 | 134,453 | Jan 28 06:00 PM | BARUCH THOMAS R | Director | Dec 28 | Sale | 15.98 | 12,500 | 199,725 | 103,093 | Dec 31 07:14 PM | BARUCH THOMAS R | Director | Dec 27 | Sale | 16.09 | 12,500 | 201,076 | 115,593 | Dec 31 07:14 PM | WOLF DENNIS P | Director | Dec 26 | Sale | 15.83 | 9,000 | 142,425 | 86,230 | Dec 28 08:17 PM | KELLEY BERNARD J | Director | Dec 21 | Sale | 16.98 | 10,206 | 173,316 | 205,255 | Dec 26 05:15 PM | Yang Patrick Y | Director | Dec 20 | Sale | 17.82 | 25,000 | 445,492 | 53,817 | Dec 21 06:39 PM | Yang Patrick Y | Director | Dec 19 | Sale | 19.22 | 25,000 | 480,458 | 78,817 | Dec 21 06:39 PM | NICOLS JOHN J | President and CEO | Dec 07 | Option Exercise | 3.46 | 3,812 | 13,190 | 1,076,491 | Dec 10 05:36 PM | NICOLS JOHN J | President and CEO | Dec 07 | Sale | 22.09 | 3,812 | 84,209 | 1,072,679 | Dec 10 05:36 PM | NICOLS JOHN J | President and CEO | Dec 06 | Option Exercise | 3.46 | 40,000 | 138,400 | 1,112,679 | Dec 10 05:36 PM | NICOLS JOHN J | President and CEO | Dec 06 | Sale | 21.75 | 40,000 | 869,832 | 1,072,679 | Dec 10 05:36 PM | Lalonde James | SVP, R&D | Nov 13 | Sale | 15.22 | 6,726 | 102,395 | 151,317 | Nov 14 07:11 PM | Lalonde James | SVP, R&D | Nov 12 | Sale | 15.57 | 6,727 | 104,716 | 158,043 | Nov 14 07:11 PM | SANGSTER GORDON | SVP & Chief Financial Officer | Oct 03 | Option Exercise | 17.11 | 40,000 | 684,516 | 174,453 | Oct 04 06:36 PM | SANGSTER GORDON | SVP & Chief Financial Officer | Oct 03 | Sale | 17.11 | 40,000 | 684,516 | 134,453 | Oct 04 06:36 PM | SANGSTER GORDON | SVP & Chief Financial Officer | Oct 02 | Option Exercise | 16.76 | 40,000 | 670,476 | 174,453 | Oct 04 06:36 PM | SANGSTER GORDON | SVP & Chief Financial Officer | Oct 02 | Sale | 16.76 | 40,000 | 670,476 | 134,453 | Oct 04 06:36 PM | NICOLS JOHN J | President and CEO | Sep 28 | Option Exercise | 3.46 | 40,000 | 138,400 | 1,112,679 | Oct 01 09:52 PM | NICOLS JOHN J | President and CEO | Sep 28 | Sale | 17.43 | 40,000 | 697,324 | 1,072,679 | Oct 01 09:52 PM | NICOLS JOHN J | President and CEO | Sep 27 | Option Exercise | 3.46 | 40,000 | 138,400 | 1,112,679 | Oct 01 09:52 PM | NICOLS JOHN J | President and CEO | Sep 27 | Sale | 17.71 | 40,000 | 708,349 | 1,072,679 | Oct 01 09:52 PM | BARUCH THOMAS R | Director | Sep 27 | Sale | 18.07 | 12,500 | 225,904 | 128,093 | Sep 28 07:42 PM | BARUCH THOMAS R | Director | Sep 26 | Sale | 19.00 | 12,500 | 237,489 | 140,593 | Sep 28 07:42 PM | WOLF DENNIS P | Director | Sep 26 | Sale | 19.17 | 9,000 | 172,522 | 95,230 | Sep 28 07:46 PM | Glaub Kathleen Sereda | Director | Sep 25 | Sale | 18.83 | 14,492 | 272,816 | 63,534 | Sep 27 05:18 PM | KELLEY BERNARD J | Director | Sep 21 | Sale | 18.12 | 10,207 | 184,959 | 215,461 | Sep 25 09:19 PM | Yang Patrick Y | Director | Sep 19 | Sale | 17.94 | 25,000 | 448,428 | 103,817 | Sep 20 06:30 PM | Glaub Kathleen Sereda | Director | Sep 19 | Sale | 17.94 | 20,094 | 360,390 | 78,026 | Sep 20 06:40 PM | Yang Patrick Y | Director | Sep 18 | Sale | 18.47 | 25,000 | 461,750 | 128,817 | Sep 20 06:30 PM | Lalonde James | SVP, R&D | Sep 05 | Sale | 17.35 | 12,381 | 214,849 | 164,770 | Sep 06 05:17 PM | Lalonde James | SVP, R&D | Sep 04 | Sale | 17.16 | 17,915 | 307,348 | 177,151 | Sep 06 05:17 PM | KELLEY BERNARD J | Director | Aug 30 | Option Exercise | 7.46 | 16,666 | 124,328 | 242,334 | Sep 04 09:03 PM | KELLEY BERNARD J | Director | Aug 30 | Sale | 17.15 | 16,666 | 285,780 | 225,668 | Sep 04 09:03 PM | SANGSTER GORDON | SVP & Chief Financial Officer | Aug 21 | Sale | 15.31 | 18,736 | 286,906 | 134,453 | Aug 23 05:19 PM | WOLF DENNIS P | Director | Aug 20 | Option Exercise | 10.51 | 18,333 | 192,680 | 122,563 | Aug 21 06:10 PM | WOLF DENNIS P | Director | Aug 20 | Sale | 15.24 | 18,333 | 279,404 | 104,230 | Aug 21 06:10 PM | WOLF DENNIS P | Director | Aug 17 | Option Exercise | 10.88 | 18,333 | 199,513 | 122,563 | Aug 21 06:10 PM | WOLF DENNIS P | Director | Aug 17 | Sale | 14.71 | 18,333 | 269,612 | 104,230 | Aug 21 06:10 PM | Yang Patrick Y | Director | Aug 16 | Sale | 14.45 | 150,340 | 2,172,413 | 0 | Aug 20 08:51 PM | NICOLS JOHN J | President and CEO | Aug 15 | Option Exercise | 3.46 | 2,400 | 8,304 | 1,075,079 | Aug 16 05:28 PM | NICOLS JOHN J | President and CEO | Aug 15 | Sale | 14.90 | 2,400 | 35,760 | 1,072,679 | Aug 16 05:28 PM | NICOLS JOHN J | President and CEO | Aug 14 | Option Exercise | 3.46 | 11,859 | 41,032 | 1,084,538 | Aug 16 05:28 PM | NICOLS JOHN J | President and CEO | Aug 14 | Sale | 15.19 | 11,859 | 180,180 | 1,072,679 | Aug 16 05:28 PM | Yang Patrick Y | Director | Jul 19 | Sale | 15.52 | 25,000 | 387,983 | 304,157 | Jul 20 06:36 PM | Yang Patrick Y | Director | Jul 18 | Sale | 15.40 | 25,000 | 384,920 | 329,157 | Jul 20 06:36 PM | Glaub Kathleen Sereda | Director | Jul 18 | Sale | 15.34 | 10,000 | 153,400 | 98,120 | Jul 20 06:37 PM | Lalonde James | SVP, R&D | Jul 17 | Sale | 15.27 | 7,500 | 114,553 | 195,066 | Jul 18 06:22 PM | Lalonde James | SVP, R&D | Jul 16 | Sale | 15.53 | 7,500 | 116,457 | 202,566 | Jul 18 06:22 PM | Dorgan Byron L | Director | Jul 16 | Sale | 15.49 | 10,000 | 154,880 | 190,593 | Jul 17 06:37 PM | WOLF DENNIS P | Director | Jun 26 | Sale | 14.47 | 9,000 | 130,210 | 104,230 | Jun 28 06:59 PM | BARUCH THOMAS R | Director | Jun 26 | Sale | 14.38 | 12,500 | 179,775 | 153,093 | Jun 27 06:01 PM | BARUCH THOMAS R | Director | Jun 25 | Sale | 15.48 | 12,500 | 193,550 | 165,593 | Jun 27 06:01 PM | KELLEY BERNARD J | Director | Jun 21 | Sale | 16.58 | 10,206 | 169,255 | 225,668 | Jun 22 06:43 PM | WOLF DENNIS P | Director | Jun 12 | Sale | 14.41 | 8,947 | 128,967 | 113,230 | Jun 12 09:00 PM | NICOLS JOHN J | President and CEO | Jun 11 | Option Exercise | 3.46 | 1,800 | 6,228 | 1,074,479 | Jun 12 07:11 PM | NICOLS JOHN J | President and CEO | Jun 11 | Sale | 14.48 | 1,800 | 26,055 | 1,072,679 | Jun 12 07:11 PM | NICOLS JOHN J | President and CEO | Jun 08 | Option Exercise | 3.46 | 7,207 | 24,936 | 1,079,886 | Jun 12 07:11 PM | NICOLS JOHN J | President and CEO | Jun 08 | Sale | 15.35 | 7,207 | 110,645 | 1,072,679 | Jun 12 07:11 PM | SANGSTER GORDON | SVP & Chief Financial Officer | May 24 | Sale | 14.11 | 18,736 | 264,307 | 153,189 | May 25 05:38 PM | Cheng Pam P. | Director | May 22 | Sale | 14.17 | 19,607 | 277,765 | 58,719 | May 23 06:04 PM | Cheng Pam P. | Director | May 21 | Sale | 13.87 | 19,608 | 272,017 | 78,326 | May 23 06:04 PM | Aldridge Michael D. | See Remarks | May 17 | Option Exercise | 4.37 | 22,000 | 96,140 | 22,000 | May 18 05:54 PM | Aldridge Michael D. | See Remarks | May 17 | Sale | 13.54 | 22,000 | 297,865 | 0 | May 18 05:54 PM | Aldridge Michael D. | See Remarks | May 15 | Option Exercise | 4.37 | 22,000 | 96,140 | 22,000 | May 16 08:59 PM | Aldridge Michael D. | See Remarks | May 15 | Sale | 12.91 | 22,000 | 283,945 | 0 | May 16 08:59 PM | Lalonde James | SVP, R&D | May 15 | Sale | 12.90 | 10,000 | 129,030 | 210,066 | May 15 07:06 PM | Lalonde James | SVP, R&D | May 14 | Sale | 13.09 | 10,000 | 130,900 | 220,066 | May 15 07:06 PM | Smith David V | Director | Apr 03 | Sale | 10.37 | 6,000 | 62,213 | 56,679 | Apr 05 01:11 PM | BARUCH THOMAS R | Director | Mar 29 | Sale | 11.06 | 12,500 | 138,195 | 172,170 | Mar 30 11:56 AM | BARUCH THOMAS R | Director | Mar 28 | Sale | 11.05 | 12,500 | 138,123 | 184,670 | Mar 30 11:56 AM | WOLF DENNIS P | Director | Mar 27 | Sale | 11.14 | 12,500 | 139,300 | 116,254 | Mar 28 12:27 PM | WOLF DENNIS P | Director | Mar 26 | Option Exercise | 7.46 | 16,666 | 124,328 | 157,920 | Mar 28 12:27 PM | WOLF DENNIS P | Director | Mar 26 | Sale | 11.15 | 29,166 | 325,084 | 128,754 | Mar 28 12:27 PM | NICOLS JOHN J | President and CEO | Mar 23 | Option Exercise | 3.46 | 16,154 | 55,893 | 1,088,833 | Mar 23 08:30 PM | NICOLS JOHN J | President and CEO | Mar 23 | Sale | 11.43 | 16,154 | 184,655 | 1,072,679 | Mar 23 08:30 PM | NICOLS JOHN J | President and CEO | Mar 22 | Option Exercise | 3.46 | 6,311 | 21,836 | 1,078,990 | Mar 23 08:30 PM | NICOLS JOHN J | President and CEO | Mar 22 | Sale | 11.91 | 6,311 | 75,173 | 1,072,679 | Mar 23 08:30 PM |
|
 |
|
 |
|
 |
|
Index | - |
P/E | - |
EPS (ttm) | -3.75 |
Insider Own | 0.90% |
Shs Outstand | 71.82M |
Perf Week | 8.27% |
Market Cap | 9.94B |
Forward P/E | - |
EPS next Y | -3.18 |
Insider Trans | -29.19% |
Shs Float | 63.00M |
Perf Month | 16.09% |
Income | -245.00M |
PEG | - |
EPS next Q | -1.04 |
Inst Own | 96.40% |
Short Float | 15.11% |
Perf Quarter | 18.57% |
Sales | 273.90M |
P/S | 36.30 |
EPS this Y | 84.30% |
Inst Trans | 3.03% |
Short Ratio | 9.40 |
Perf Half Y | 10.13% |
Book/sh | 9.66 |
P/B | 14.33 |
EPS next Y | 28.10% |
ROA | -19.50% |
Target Price | 195.32 |
Perf Year | 132.42% |
Cash/sh | 11.04 |
P/C | 12.54 |
EPS next 5Y | -0.20% |
ROE | -33.70% |
52W Range | 59.13 - 176.50 |
Perf YTD | 26.87% |
Dividend | - |
P/FCF | - |
EPS past 5Y | 30.00% |
ROI | -14.20% |
52W High | -21.56% |
Beta | 2.10 |
Dividend % | - |
Quick Ratio | 7.80 |
Sales past 5Y | 32.90% |
Gross Margin | 91.00% |
52W Low | 134.14% |
ATR | 5.86 |
Employees | 255 |
Current Ratio | 8.80 |
Sales Q/Q | 70.70% |
Oper. Margin | -83.00% |
RSI (14) | 61.41 |
Volatility | 3.76% 4.68% |
Optionable | Yes |
Debt/Eq | 0.65 |
EPS Q/Q | -48.70% |
Profit Margin | -89.50% |
Rel Volume | 0.87 |
Prev Close | 134.88 |
Shortable | Yes |
LT Debt/Eq | 0.65 |
Earnings | Feb 28 AMC |
Payout | - |
Avg Volume | 1.01M |
Price | 138.45 |
Recom | 1.70 |
SMA20 | 7.01% |
SMA50 | 15.01% |
SMA200 | 11.88% |
Volume | 877,696 |
Change | 2.65% |
|
|
 |
|  |
Oct-12-18 | Initiated |
Bernstein |
Outperform |
|
|
Oct-01-18 | Initiated |
Cantor Fitzgerald |
Overweight |
$217 |
|
Sep-26-18 | Reiterated |
RBC Capital Mkts |
Outperform |
$187 → $200 |
|
Sep-14-18 | Resumed |
BofA/Merrill |
Buy |
$199 |
|
Sep-06-18 | Initiated |
Credit Suisse |
Outperform |
$178 |
|
Aug-01-18 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
Jun-21-18 | Reiterated |
Robert W. Baird |
Outperform |
$120 → $202 |
|
Jun-20-18 | Reiterated |
Needham |
Buy |
$109 → $204 |
|
Jun-19-18 | Reiterated |
H.C. Wainwright |
Buy |
$96 → $267 |
|
May-18-18 | Reiterated |
Goldman |
Buy |
$84 → $127 |
|
May-11-18 | Upgrade |
Barclays |
Equal Weight → Overweight |
$55 → $107 |
|
May-07-18 | Reiterated |
Needham |
Buy |
$75 → $109 |
|
May-07-18 | Reiterated |
H.C. Wainwright |
Buy |
$90 → $96 |
|
Mar-21-18 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
Mar-13-18 | Reiterated |
H.C. Wainwright |
Buy |
$75 → $92 |
|
Jan-22-18 | Initiated |
RBC Capital Mkts |
Outperform |
|
|
Jan-04-18 | Initiated |
Janney |
Buy |
$75 |
|
Dec-01-17 | Initiated |
H.C. Wainwright |
Buy |
$75 |
|
Oct-06-17 | Resumed |
Goldman |
Buy |
$71 |
|
Oct-02-17 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
|
 |
Feb-15-19 08:56AM | Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks |
Feb-14-19 04:01PM | Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A) GlobeNewswire |
08:30AM | Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 GlobeNewswire |
Feb-11-19 11:21AM | Weekly CFO Sells Highlight GuruFocus.com |
08:44AM | Implied Volatility Surging for Sarepta (SRPT) Stock Options Zacks |
Feb-07-19 08:37PM | What Solid Biosciences' First Failure Means for Sarepta Therapeutics Motley Fool |
10:45AM | Solid Biosciences shares drop 70% on disappointing Duchenne data American City Business Journals |
09:42AM | Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains Bloomberg |
Feb-05-19 10:08AM | Weekly CFO Sells Highlight GuruFocus.com |
Feb-03-19 02:04PM | 3 Gene Therapy Stocks With Huge Catalysts in 2019 Motley Fool |
Feb-01-19 12:05PM | Should You Take Comfort From Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Simply Wall St. |
09:48AM | 6 Biotech Stocks to Watch Now Motley Fool |
Jan-31-19 06:00PM | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.53% |
01:10PM | Fear of Missing Out Is the Main Driving Force in This Market TheStreet.com |
09:07AM | Your first trade for Thursday, January 31 CNBC |
07:55AM | Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE |
Jan-20-19 09:21AM | 3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs Motley Fool |
Jan-16-19 11:03AM | Here are top analysts' 5 favorite growth stocks for 2019 CNBC |
Jan-15-19 04:48PM | Heres your guide to the upcoming biotechnology takeover wave MarketWatch |
06:07AM | FDA pilot program could help Wave avoid orphan-drug pitfalls American City Business Journals |
Jan-14-19 07:25AM | Analysis: Positioning to Benefit within Alphabet, Globalstar, Ingevity, Vocera Communications, Sarepta Therapeutics, and FLIR Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
Jan-12-19 07:31AM | 3 Biotech Stocks to Watch in 2019 Motley Fool |
Jan-11-19 05:27PM | InvestorPlace Roundup: The Hottest Stocks in the Market Today InvestorPlace |
10:59AM | Why Sarepta Therapeutics Stock Is Starting to Shine Again InvestorPlace |
Jan-08-19 02:11PM | Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track Benzinga |
08:56AM | 4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks |
Jan-04-19 11:38AM | Here's Why Sarepta Therapeutics Fell 15.7% in December Motley Fool +8.21% |
Jan-03-19 08:50AM | Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply Zacks |
Jan-02-19 08:30AM | Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy GlobeNewswire |
08:00AM | Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire |
Dec-31-18 06:00PM | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
Dec-24-18 01:13PM | Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019 Investor's Business Daily |
Dec-21-18 01:36PM | 6 Genome Sequencing Stocks to Buy for Big Health-Care Profits Kiplinger |
Dec-20-18 08:30AM | Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 GlobeNewswire |
Dec-13-18 08:32AM | Ghost Tree Capitals AUM, Returns and Holdings Insider Monkey |
Dec-12-18 11:50AM | Analysts Expect Breakeven For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Simply Wall St. |
Dec-11-18 08:30AM | Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors GlobeNewswire |
Dec-08-18 10:15AM | Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy? Insider Monkey |
Dec-07-18 08:25AM | New Research Coverage Highlights Callaway Golf, Synchrony Financial, Roper Technologies, Ringcentral, Sarepta Therapeutics, and Advanced Micro Devices Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
Dec-06-18 06:50AM | Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE |
Nov-30-18 06:00PM | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
Nov-23-18 09:03AM | Sarepta Stock More Than Doubles This Year So Far: Here's Why Zacks |
Nov-16-18 07:00AM | Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics ACCESSWIRE |
Nov-12-18 04:21PM | These Biopharmas Could Cure Genetic Diseases At $5 Million Apiece Investor's Business Daily |
Nov-08-18 07:13PM | Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock GlobeNewswire -7.68% |
Nov-07-18 04:21PM | Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock GlobeNewswire +5.02% |
Nov-06-18 10:13AM | Hedge Funds Just Stormed Into This Red-Hot Biotech Company Insider Monkey |
08:43AM | Implied Volatility Surging for Sarepta Therapeutics (SPRT) Stock Options Zacks |
Nov-05-18 10:17AM | Weekly CEO Buys Highlight GuruFocus.com |
Nov-02-18 12:13PM | Weekly CFO Sells Highlight GuruFocus.com |
08:30AM | Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference GlobeNewswire |
Oct-31-18 06:00PM | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.50% |
08:00AM | Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics ACCESSWIRE |
Oct-30-18 09:15PM | Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares GuruFocus.com +6.46% |
08:00AM | Report: Exploring Fundamental Drivers Behind Sarepta Therapeutics, Reinsurance Group of America, Illinois Tool Works, ATN International, Morningstar, and Hubbell New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
Oct-29-18 12:09PM | 7 Rising Healthcare Stocks to Consider InvestorPlace |
Oct-26-18 08:15AM | Edited Transcript of SRPT earnings conference call or presentation 24-Oct-18 8:30pm GMT Thomson Reuters StreetEvents |
Oct-25-18 11:06AM | Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up Zacks |
Oct-24-18 07:00PM | Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates Zacks -8.40% |
05:53PM | Sarepta Therapeutics: 3Q Earnings Snapshot Associated Press |
04:06PM | Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire |
08:22AM | Q3 Earnings Preview For Sarepta Therapeutics Benzinga |
Oct-23-18 09:31AM | Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks |
Oct-18-18 04:30PM | Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018 GlobeNewswire |
Oct-17-18 11:40AM | Duchenne biotech Sarepta to open gene therapy facility in Ohio American City Business Journals |
10:32AM | Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect Zacks |
10:00AM | Sarepta Announces Agreement With Lysogene for Gene Therapy Zacks |
Oct-16-18 04:12PM | Boston biopharma commercializing Nationwide Children's gene therapies to add Columbus office, 100 jobs American City Business Journals +5.51% |
Oct-15-18 08:00AM | Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Amicus Therapeutics ACCESSWIRE |
08:00AM | Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate GlobeNewswire |
Oct-12-18 01:46PM | Are Sarepta Therapeutics Incs (NASDAQ:SRPT) Interest Costs Too High? Simply Wall St. +6.96% |
Oct-11-18 02:55PM | Sarepta CEO charts path forward on Duchenne drug amid stock slide American City Business Journals |
11:11AM | Square Continues to See Extreme Pressure TheStreet.com |
10:10AM | Here's Why Sarepta Therapeutics Jumped 17% in September Motley Fool |
Oct-08-18 08:30AM | Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies GlobeNewswire |
Oct-05-18 08:30AM | Sarepta Announces Agreement with Nationwide Childrens Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder GlobeNewswire -5.47% |
Oct-04-18 08:00AM | Today's Research Reports on Trending Tickers: Tesaro and Sarepta Therapeutics ACCESSWIRE |
07:59AM | The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut Benzinga |
Oct-03-18 05:15PM | Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire |
Oct-02-18 01:18PM | Overall Market Breadth Remains Negative TheStreet.com |
08:00AM | Today's Research Reports on Trending Tickers: Omeros and Sarepta Therapeutics ACCESSWIRE |
Oct-01-18 10:28AM | 5 Best Biotech Stocks to Buy In October Zacks -7.89% |
Sep-28-18 06:00PM | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire |
Sep-26-18 08:30AM | Sarepta Therapeutics and Jerry R. Mendell, M.D. from Nationwide Childrens Hospital to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society GlobeNewswire |
08:26AM | Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars Zacks |
Sep-25-18 10:44AM | FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program Zacks |
Sep-24-18 04:43PM | CHMP Reconfirms Negative Opinion for Sarepta's Exondys Zacks |
08:19AM | Sarepta stock rises after FDA lifts clinical hold on gene therapy program MarketWatch |
07:00AM | Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program GlobeNewswire |
Sep-21-18 12:01PM | Sarepta investors, analysts shrug off E.U. setback for Duchenne drug American City Business Journals |
06:48AM | Sarepta expected, but is disappointed by European regulators decision on DMD treatment MarketWatch |
06:30AM | Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen GlobeNewswire |
Sep-12-18 01:10PM | Corrective Action in This Market Is Often Quite Hidden TheStreet.com +5.07% |
Sep-11-18 07:43PM | Why Sarepta Therapeutics, Inc. Stock Jumped 18.8% Higher in August Motley Fool |
Sep-10-18 02:17PM | Six Biotechnology Names on My Watch List TheStreet.com |
Sep-07-18 05:05PM | Sarepta Therapeutics CEO has a 'big ambition' for muscular dystrophy gene therapy CNBC |
03:34PM | Sarepta Therapeutics CEO on soaring stock and drug develo... CNBC Videos |
09:30AM | Why Is Sarepta Therapeutics (SRPT) Up 6.4% Since Last Earnings Report? Zacks |
09:15AM | Today's Bell Ringer, September 7, 2018 CNBC Videos |
08:30AM | Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony GlobeNewswire |
|
|
|
 |
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Mahatme Sandesh | EVP, CFO & CBO | Feb 07 | Option Exercise | 23.85 | 65,000 | 1,550,250 | 73,649 | Feb 08 08:02 PM | Mahatme Sandesh | EVP, CFO & CBO | Feb 07 | Sale | 145.00 | 65,000 | 9,425,000 | 8,649 | Feb 08 08:02 PM | Cumbo Alexander | SVP, Chief Commercial Officer | Feb 01 | Option Exercise | 22.54 | 7,500 | 169,035 | 30,266 | Feb 01 08:27 PM | Howton David T | SVP, General Counsel | Feb 01 | Option Exercise | 21.65 | 21,500 | 465,391 | 49,571 | Feb 01 08:25 PM | Howton David T | SVP, General Counsel | Feb 01 | Sale | 140.00 | 30,000 | 4,200,000 | 19,571 | Feb 01 08:25 PM | Cumbo Alexander | SVP, Chief Commercial Officer | Feb 01 | Sale | 140.00 | 15,000 | 2,100,000 | 15,266 | Feb 01 08:27 PM | Mahatme Sandesh | EVP, CFO & CBO | Jan 31 | Option Exercise | 23.85 | 21,198 | 505,572 | 29,847 | Feb 01 08:24 PM | Mahatme Sandesh | EVP, CFO & CBO | Jan 31 | Sale | 130.72 | 21,198 | 2,771,003 | 8,649 | Feb 01 08:24 PM | Mahatme Sandesh | EVP, CFO & CBO | Jan 30 | Option Exercise | 18.27 | 43,802 | 800,077 | 52,451 | Feb 01 08:24 PM | Mahatme Sandesh | EVP, CFO & CBO | Jan 30 | Sale | 130.00 | 43,802 | 5,694,260 | 8,649 | Feb 01 08:24 PM | Wigzell Hans Lennart Rudolf | Director | Nov 01 | Option Exercise | 8.94 | 6,667 | 59,603 | 16,751 | Nov 02 06:01 PM | Wigzell Hans Lennart Rudolf | Director | Nov 01 | Sale | 140.50 | 6,667 | 936,714 | 10,084 | Nov 02 06:01 PM | BEHRENS M KATHLEEN | Director | Oct 31 | Option Exercise | 3.96 | 10,000 | 39,600 | 126,534 | Nov 02 06:00 PM | BEHRENS M KATHLEEN | Director | Oct 31 | Sale | 131.71 | 10,000 | 1,317,100 | 116,534 | Nov 02 06:00 PM | INGRAM DOUGLAS S | President & CEO | Oct 30 | Buy | 120.39 | 16,695 | 2,009,872 | 415,945 | Oct 30 07:05 PM | Mahatme Sandesh | EVP, CFO & CBO | Oct 24 | Option Exercise | 14.88 | 89,400 | 1,330,389 | 128,185 | Oct 26 06:43 PM | Mahatme Sandesh | EVP, CFO & CBO | Oct 24 | Sale | 127.74 | 107,524 | 13,735,116 | 20,661 | Oct 26 06:43 PM | INGRAM DOUGLAS S | President & CEO | Aug 15 | Buy | 125.26 | 16,000 | 2,004,211 | 399,250 | Aug 16 07:30 AM | Howton David T | SVP, General Counsel | Jul 16 | Option Exercise | 13.85 | 50,000 | 692,691 | 72,719 | Jul 17 06:01 PM | Howton David T | SVP, General Counsel | Jul 16 | Sale | 136.46 | 50,000 | 6,823,000 | 34,871 | Jul 17 06:01 PM | Cumbo Alexander | SVP, Chief Commercial Officer | Jul 09 | Option Exercise | 13.78 | 33,782 | 465,415 | 40,690 | Jul 11 06:05 PM | Cumbo Alexander | SVP, Chief Commercial Officer | Jul 09 | Sale | 137.32 | 33,782 | 4,638,944 | 28,766 | Jul 11 06:05 PM | Barry Richard | Director | Jun 27 | Sale | 130.34 | 75,000 | 9,775,500 | 3,170,432 | Jun 29 06:01 PM | Cumbo Alexander | SVP, Chief Commercial Officer | Mar 15 | Option Exercise | 20.64 | 2,500 | 51,600 | 25,767 | Mar 16 06:10 PM | Mahatme Sandesh | EVP, CFO & CBO | Mar 15 | Option Exercise | 23.85 | 2,500 | 59,625 | 43,395 | Mar 16 06:08 PM | Howton David T | SVP, General Counsel | Mar 15 | Option Exercise | 22.15 | 2,500 | 55,382 | 31,727 | Mar 16 06:12 PM | Ruff Shamim | SVP, Chief Regulatory Affairs | Mar 15 | Option Exercise | 23.93 | 2,500 | 59,813 | 29,465 | Mar 16 06:13 PM |
|
 |
|
 |
|